Actos has been recalled in the European countries Germany and France due evidence the world’s best selling diabetes medication increases the risk of bladder cancer. While the F.D.A in the United States has only changed the labeling of Actos to reflect the increased risk of bladder cancer.
The minor label change to the U.S. version of Actos by the F.D.A. is a major indication a real problem exists with the drugs intended purpose and its unfortunate side effects. The specific change or addition in this case to the label was, “that the use of pioglitazone (Actos) for more than one year may be associated with an increased risk of bladder cancer.”
The study that triggered the ban of Actos in Europe and caused the not so flattering label change in the U.S. found that Actos increased a patient’s risk for bladder cancer by 40%. This study examined the first 5 years of a 10 year study conducted by Takeda, manufacturer of Actos.
If you have been taking Actos for more than a year please contact our offices so that we may have your information on file for any future actions.
August 11, 2011
4 Comments